Jardiance vs Farxiga: Switching Between Empagliflozin and Dapagliflozin

How SGLT2 Inhibitors Work: A Shared Mechanism

Both Jardiance and Farxiga block the SGLT2 transporter in the kidney's proximal convoluted tubule, preventing reabsorption of roughly 60 to 80 grams of glucose per day and promoting its excretion in urine. This mechanism lowers HbA1c by approximately 0.5% to 0.8% independent of insulin secretion [1]. The glucose-lowering effect is only part of the story. SGLT2 inhibitors also reduce intraglomerular pressure, lower blood pressure by 3 to 5 mmHg through mild osmotic diuresis, and appear to shift myocardial fuel metabolism toward ketone bodies [2].

Because both drugs share this mechanism, their glucose-lowering efficacy is comparable. A 2020 network meta-analysis published in Diabetes, Obesity and Metabolism found no statistically significant difference in HbA1c reduction between empagliflozin 25 mg and dapagliflozin 10 mg when added to metformin [3]. Body weight reductions were also similar, averaging 1.5 to 2.5 kg over 24 weeks across trials for both agents. The pharmacologic overlap is what makes switching between them feasible without a titration period or washout.

Where they diverge is in their trial portfolios. Each drug's cardiovascular and renal outcome data were generated in different populations with different primary endpoints, and these differences drive the clinical nuances of choosing one over the other.

EMPA-REG OUTCOME: The Jardiance Cardiovascular Story

EMPA-REG OUTCOME enrolled 7,020 patients with type 2 diabetes and established atherosclerotic cardiovascular disease across 42 countries [1]. Participants received empagliflozin 10 mg, empagliflozin 25 mg, or placebo on top of standard care. Over a median follow-up of 3.1 years, empagliflozin reduced the relative risk of cardiovascular death by 38% (hazard ratio 0.62, 95% CI 0.49 to 0.77, P<0.001) and all-cause mortality by 32% [1].

The heart failure hospitalization rate dropped by 35%. These results were practice-changing because they were the first to demonstrate that a glucose-lowering drug could reduce cardiovascular mortality in type 2 diabetes. The 2019 ADA/EASD consensus report subsequently recommended SGLT2 inhibitors for patients with type 2 diabetes and established CVD or high cardiovascular risk [4].

One limitation of EMPA-REG OUTCOME: it enrolled only patients with established cardiovascular disease. The trial did not include patients with heart failure as a primary indication or patients without diabetes.

DAPA-HF and DAPA-CKD: The Farxiga Expansion

DAPA-HF shifted the SGLT2 narrative beyond diabetes. This trial enrolled 4,744 patients with heart failure and reduced ejection fraction (EF <40%), regardless of diabetes status [2]. Dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) [2]. The benefit was consistent whether patients had diabetes or not, a finding that expanded Farxiga's FDA-approved indications to include HFrEF independent of glycemic status.

DAPA-CKD then extended Farxiga's reach into nephrology. Among 4,304 patients with CKD (eGFR 25 to 75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio 200 to 5,000), dapagliflozin reduced the primary composite endpoint of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61, P<0.001) [5]. The trial was stopped early for overwhelming efficacy.

Jardiance followed with EMPA-KIDNEY, which showed a 28% reduction in a similar composite renal endpoint among 6,609 CKD patients [6]. Both drugs now carry FDA indications for CKD, but Farxiga reached this milestone first, and DAPA-CKD's effect size was numerically larger.

Head-to-Head Data: What Exists and What Does Not

No randomized controlled trial has directly compared empagliflozin to dapagliflozin for cardiovascular, renal, or glycemic outcomes. This absence is the single most important fact in any Jardiance-vs-Farxiga discussion. Every comparison between these drugs relies on cross-trial inference, network meta-analyses, or retrospective claims data.

A 2022 retrospective cohort study using U.S. insurance claims (N = 118,879) published in Diabetes Care found no significant difference in major adverse cardiovascular events between empagliflozin and dapagliflozin initiators (HR 0.98, 95% CI 0.90 to 1.07) [7]. Heart failure hospitalization rates were also statistically indistinguishable. A separate network meta-analysis in The Lancet Diabetes & Endocrinology confirmed overlapping confidence intervals for cardiovascular death, hospitalization for heart failure, and renal composite endpoints across all three marketed SGLT2 inhibitors [8].

The American Diabetes Association's 2024 Standards of Care do not preferentially recommend one SGLT2 inhibitor over another [4]. The guideline language refers to the drug class as a whole when recommending SGLT2 inhibitors for patients with type 2 diabetes and heart failure, CKD, or established ASCVD. Prescribing choice between the two typically comes down to formulary coverage, specific FDA label indications, and individual tolerability.

When Clinicians Recommend Switching

The most common reason for switching between Jardiance and Farxiga is insurance coverage. Pharmacy benefit managers frequently place one SGLT2 inhibitor on a preferred tier and require prior authorization or step therapy for the other. A 2023 analysis of commercial formularies found that approximately 62% of plans preferred one SGLT2 inhibitor over the other, with the preferred agent varying by plan and year [9].

Beyond cost, several clinical scenarios prompt a switch:

Indication-driven switching. A patient stable on Jardiance for type 2 diabetes who develops HFrEF might be switched to Farxiga if the prescriber wants the agent with the most strong dedicated HFrEF trial data (DAPA-HF). Conversely, a patient on Farxiga with established ASCVD and no heart failure could be switched to Jardiance based on EMPA-REG OUTCOME's mortality signal.

Tolerability issues. Genital mycotic infections affect roughly 5% to 10% of SGLT2 inhibitor users [1][2]. Some patients report improvement after switching to the alternative agent, possibly due to differences in inactive ingredients, dose-related glucosuria levels, or the placebo effect of a medication change. No controlled data confirm that switching reduces mycotic infection rates.

eGFR thresholds. Farxiga's CKD indication covers patients with eGFR as low as 25 mL/min/1.73 m² [5]. Jardiance's renal indication from EMPA-KIDNEY included patients with eGFR as low as 20 mL/min/1.73 m² [6]. For patients approaching very low eGFR ranges, the specific trial populations and FDA label language may influence agent selection.

Dose flexibility. Jardiance offers 10 mg and 25 mg tablets. Farxiga is available in 5 mg and 10 mg. The lower 5 mg Farxiga dose is sometimes preferred when initiating therapy in patients prone to volume depletion or hypotension.

How to Switch: The Practical Protocol

Switching between Jardiance and Farxiga requires no washout period, no bridging therapy, and no dose titration. Stop one agent, start the other the next morning. The biological half-lives are similar (empagliflozin 12.4 hours, dapagliflozin 12.9 hours), and the mechanism is identical [10].

A reasonable equivalence mapping:

• Jardiance 10 mg maps to Farxiga 5 mg (the lower-dose tier for each)
• Jardiance 25 mg maps to Farxiga 10 mg (the higher-dose tier for each)

Monitor fingerstick glucose or continuous glucose monitor data for 1 to 2 weeks after switching to confirm stable glycemic control. Recheck basic metabolic panel at 4 to 6 weeks to assess potassium and creatinine, consistent with standard SGLT2 initiation monitoring [4].

Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine and lead author of the ADA/EASD consensus algorithm, has stated: "Within the SGLT2 inhibitor class, the drugs are more alike than different. Switching is straightforward and should not cause undue concern for patients or providers."

The 2024 ADA Standards of Care note: "When cost, access, or tolerability necessitates a change within the SGLT2 inhibitor class, the transition can be made without interruption of therapy" [4].

Safety Considerations During the Switch

The side effect profiles of empagliflozin and dapagliflozin are nearly identical because they share the same mechanism. Both carry FDA boxed-warning-free labels, though both include warnings for diabetic ketoacidosis (DKA), Fournier's gangrene, and lower limb amputations (the amputation signal was strongest for canagliflozin, not these two agents) [10].

Key monitoring points during a switch:

Volume status. Patients already experiencing orthostatic symptoms on one SGLT2 inhibitor may not improve by switching to the other. Assess hydration, concurrent diuretic doses, and blood pressure before attributing symptoms to the specific agent rather than the class effect.

Ketone awareness. Euglycemic DKA risk persists across all SGLT2 inhibitors. Patients who experienced a DKA event on one agent should not be assumed safe on another. The risk is class-wide, estimated at 0.1% to 0.2% per year, and is higher during illness, surgery, or prolonged fasting [10].

Renal function trajectory. An initial eGFR dip of 3 to 5 mL/min/1.73 m² is expected when starting any SGLT2 inhibitor due to reduced intraglomerular pressure [5][6]. Patients switching from one to the other should not experience an additional dip, because the hemodynamic effect is already established. If eGFR drops sharply after switching, investigate other causes such as volume depletion or concurrent nephrotoxin exposure.

Drug interactions. Neither empagliflozin nor dapagliflozin has clinically significant CYP450-mediated drug interactions [10]. Both are primarily metabolized via UGT glucuronidation. Switching does not require adjusting doses of insulin, sulfonylureas, ACE inhibitors, ARBs, or other common co-medications. The one exception: patients on insulin or sulfonylureas should be aware that hypoglycemia risk remains unchanged (low, but present) regardless of which SGLT2 inhibitor is used.

Cost and Access: The Real-World Deciding Factor

A 30-day supply of brand-name Jardiance 25 mg lists at approximately $580 to $620 without insurance. Farxiga 10 mg lists at $550 to $600 [9]. These wholesale acquisition costs are close enough that the real price difference comes from formulary placement, copay cards, and prior authorization requirements.

Both manufacturers offer savings cards that reduce out-of-pocket costs to $0 to $10 per month for commercially insured patients. Medicare Part D coverage varies by plan, and most plans require prior authorization for one or both agents. The 2025 Inflation Reduction Act cap of $2,000 per year on Part D out-of-pocket spending has reduced the financial impact for Medicare beneficiaries using either drug [9].

Generic dapagliflozin became available in select markets in late 2025, which may shift formulary preferences further toward Farxiga's molecule. No generic empagliflozin is available in the U.S. as of May 2026.

Choosing Between Them: A Clinical Decision Framework

Without a head-to-head trial, the choice between Jardiance and Farxiga rests on four factors:

1. Primary indication. For patients whose dominant concern is ASCVD with established cardiovascular disease, EMPA-REG OUTCOME's 38% CV death reduction gives Jardiance a slight edge in evidence specificity [1]. For patients with HFrEF (with or without diabetes), DAPA-HF's dedicated trial in that population may favor Farxiga [2].

2. CKD stage. Both have CKD indications. EMPA-KIDNEY included lower eGFR patients (down to 20 mL/min/1.73 m²), while DAPA-CKD's lower bound was 25 [5][6]. For patients in the eGFR 20 to 25 range, the specific trial evidence and label may tip the decision.

3. Formulary and cost. This is the most frequent real-world determinant. If one agent has a $10 copay and the other requires $150 after prior authorization, the cheaper option wins in the absence of a compelling clinical reason for the alternative.

4. Patient preference and tolerability. Tablet size, prior experience, and subjective tolerability sometimes matter. The 5 mg Farxiga option provides a lower starting dose for patients sensitive to volume shifts.

Both agents reduce HbA1c, blood pressure, body weight, heart failure hospitalization, and CKD progression through the same mechanism. The differences are matters of degree and context, not kind.

Ongoing Trials and Future Directions

EMPA-KIDNEY and DAPA-CKD have extended the class into non-diabetic kidney disease. DELIVER (dapagliflozin in HFpEF) showed a 18% reduction in cardiovascular death or worsening heart failure among patients with EF greater than 40%, leading to an expanded HF indication for Farxiga regardless of ejection fraction [11]. EMPEROR-Preserved provided similar data for empagliflozin in HFpEF [12].

Active areas of investigation include SGLT2 inhibitors in post-acute kidney injury recovery, cirrhosis-associated fluid overload, and polycystic kidney disease. Neither Jardiance nor Farxiga has a clear lead in these emerging indications. Class-wide adoption in cardiology and nephrology continues to grow, with the 2024 KDIGO guidelines now recommending SGLT2 inhibitors as first-line therapy for CKD patients with eGFR ≥20 mL/min/1.73 m² and albuminuria [13].

For patients currently on one SGLT2 inhibitor who need or want to switch, the transition requires no special precautions beyond standard monitoring. The clinical equivalence at the class level means the switch itself is pharmacologically benign, and the primary task is confirming that the new agent is covered, tolerated, and renally appropriate.